Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Medical University of South Carolina
Dana-Farber Cancer Institute
University of Chicago
Medical College of Wisconsin
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Ohio State University Comprehensive Cancer Center
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
University of California, San Diego
Ottawa Hospital Research Institute
M.D. Anderson Cancer Center
University of Utah
Mayo Clinic
M.D. Anderson Cancer Center
Vitebsk Regional Clinical Cancer Centre
Icahn School of Medicine at Mount Sinai
Columbia University
University Hospital Heidelberg
M.D. Anderson Cancer Center
University of Nebraska
M.D. Anderson Cancer Center
University of Nebraska
OHSU Knight Cancer Institute
Jewish General Hospital
Massachusetts General Hospital
Dana-Farber Cancer Institute
Columbia University
Fred Hutchinson Cancer Center
Arbeitsgemeinschaft medikamentoese Tumortherapie
Northwestern University
Shenzhen Institute for Innovation and Translational Medicine
Karolinska University Hospital
Chinese PLA General Hospital
Masonic Cancer Center, University of Minnesota
Mayo Clinic
Mayo Clinic
Mayo Clinic
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Alliance for Clinical Trials in Oncology